Weekly company factor report
VTGN Valuation, Quality and Momentum
VistaGen Therapeutics Inc
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Current factor profile
The valuation is low, but financial strength is weak. Check the F-Score, cash conversion and debt before relying on the valuation. The completed price record is weak and does not support the other measures yet. Measured price variability is high and should be considered separately from the return figures.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for VTGN.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Value measures compared
Raw multiples and yields
Valuation history is not yet established
No positive earnings base is available in the accepted history. P/E is not meaningful while earnings are zero or negative.
15 earlier weekly observations had no valid positive-earnings P/E.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Current reading
Conservative balance sheet with D/E of 0.46.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
The 12-month return excluding the latest month is -92%, showing a negative completed price record. Near-term vol (204%) is expanding vs long-term (120%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.480 | Unchanged for 0 snapshots | improving |
| Value %ile | 0.480 | Unchanged for 0 snapshots | improving |
| Quality %ile | 0.460 | Unchanged for 0 snapshots | improving |
| Momentum %ile | 0.480 | Unchanged for 0 snapshots | improving |
| F-Score | 3.000 | Unchanged for 15 snapshots | stable |
| Confidence | 0.758 | Unchanged for 15 snapshots | improving |
| Volatility | 1.197 | Unchanged for 15 snapshots | improving |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals Inc | 99.0 | 97.0 | 97.0 | 98.0 |
| NUTX Nutex Health Inc | 99.0 | 94.0 | 98.0 | 95.0 |
| THC Tenet Healthcare Corporation | 98.0 | 92.0 | 92.0 | 82.0 |
| CGEN Compugen | 98.0 | 85.0 | 96.0 | 93.0 |
| AMN AMN Healthcare Services Inc | 97.0 | 96.0 | 65.0 | 93.0 |
| MD Mednax Inc | 97.0 | 88.0 | 87.0 | 90.0 |
| HRMY Harmony Biosciences Holdings | 97.0 | 90.0 | 98.0 | 76.0 |
| OSCR Oscar Health Inc | 96.0 | 88.0 | 77.0 | 91.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Quarterly figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 11 Sep 2026
The evidence is limited by the current risk reading
The company record needs stronger support before the valuation is relied upon.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- 2 Company recordNeeds more evidence · 39/100 Checks profitability, cash support, balance-sheet measures and their direction.
- 3 Relative valueNot reached · 48/100 Checks whether the current valuation compares well with the selected market.
- 4 Market supportNot reached · 24/100 Checks completed price performance, relative strength, trend and buying pressure.
- 5 Setup and riskNot reached · 13/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewNot reached Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 46/100
- F-Score 3/9
- 5 usable annual periods
- Value rank 48/100
- P/E Not available
- Free-cash-flow yield Not available
- Price-performance rank 48/100
- Six-month return -61.0%
- Relative strength -0.9
- Stage 4 · Declining
- Stage 4 · Declining
- Price at -95.2% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 119.7%
- Recent volatility 204.0%
- 12-month drawdown -95.4%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
What still needs attention
- Company record scores 39/100.
- Relative value scores 48/100.
- Market support scores 24/100.
- Setup scores 13/100.
Next check
Check the accepted company figures, cash conversion and balance-sheet measures.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for VTGN are shown.